MX2020006533A - Inhibidores del receptor activado por proteasa-2. - Google Patents

Inhibidores del receptor activado por proteasa-2.

Info

Publication number
MX2020006533A
MX2020006533A MX2020006533A MX2020006533A MX2020006533A MX 2020006533 A MX2020006533 A MX 2020006533A MX 2020006533 A MX2020006533 A MX 2020006533A MX 2020006533 A MX2020006533 A MX 2020006533A MX 2020006533 A MX2020006533 A MX 2020006533A
Authority
MX
Mexico
Prior art keywords
sub
inhibitors
activated receptor
protease activated
par
Prior art date
Application number
MX2020006533A
Other languages
English (en)
Inventor
Bernard Luke Flynn
Luigi Aurelio
Nigel Bunnett
Le Giang
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017905084A external-priority patent/AU2017905084A0/en
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2020006533A publication Critical patent/MX2020006533A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere generalmente a compuestos capaces de inhibir el Receptor Activado por Proteasa-2 (PAR2). y sus usos. Más específicamente. la presente invención se refiere a inhibidores de PAR2, a su preparación y a su uso en el tratamiento de enfermedades y trastornos mediados por la señalización de PAR2.
MX2020006533A 2017-12-20 2018-12-19 Inhibidores del receptor activado por proteasa-2. MX2020006533A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017905084A AU2017905084A0 (en) 2017-12-20 Inhibitors of Protease Activated Receptor-2
PCT/JP2018/047988 WO2019124567A1 (en) 2017-12-20 2018-12-19 Inhibitors of protease activated receptor-2

Publications (1)

Publication Number Publication Date
MX2020006533A true MX2020006533A (es) 2020-12-09

Family

ID=65244543

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006533A MX2020006533A (es) 2017-12-20 2018-12-19 Inhibidores del receptor activado por proteasa-2.

Country Status (10)

Country Link
US (1) US20200383985A1 (es)
EP (1) EP3727386A1 (es)
JP (1) JP2021508692A (es)
CN (1) CN111698991A (es)
AU (1) AU2018388104A1 (es)
BR (1) BR112020012589A2 (es)
CA (1) CA3086458A1 (es)
EA (1) EA202091524A1 (es)
MX (1) MX2020006533A (es)
WO (1) WO2019124567A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017268039A1 (en) * 2016-05-20 2018-12-06 Takeda Pharmaceutical Company Limited Treatment of pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080317767A1 (en) 2004-04-08 2008-12-25 Tobias Braxmeier Tripartitle Raftophilic Strutures and their Use
JP4896870B2 (ja) * 2004-04-08 2012-03-14 ヤード・テヒノロギース・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞膜ラフトと相互作用する構造を含む三者複合体およびその使用
AU2014326596B2 (en) * 2013-09-25 2018-12-13 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway
AU2017268039A1 (en) * 2016-05-20 2018-12-06 Takeda Pharmaceutical Company Limited Treatment of pain

Also Published As

Publication number Publication date
BR112020012589A2 (pt) 2020-11-24
CA3086458A1 (en) 2019-06-27
US20200383985A1 (en) 2020-12-10
AU2018388104A1 (en) 2020-07-09
EA202091524A1 (ru) 2020-09-16
CN111698991A (zh) 2020-09-22
JP2021508692A (ja) 2021-03-11
WO2019124567A1 (en) 2019-06-27
EP3727386A1 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
DOP2018000010A (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
PH12019500204A1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
SA518391624B1 (ar) Ror- منظمات جاما
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
SG10201804868PA (en) Compounds for the inhibition of indoleamine-2,3-dioxygenase
MX2018010374A (es) Inhibidores del enlace proteína-proteína de wdr5.
TN2016000238A1 (en) Tricyclic compounds as anticancer agents.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2019002438A (es) Compuestos triciclicos fusionados de piridazinona utiles para tratar infecciones de orthomyxovirus.
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
EA202191115A1 (ru) Новые пиридазины
MX2022011564A (es) Tratamiento del dolor.
MX2020006533A (es) Inhibidores del receptor activado por proteasa-2.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
GB2553685A (en) Novel éthynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis